CAMBRIDGE, England, July 8 /PRNewswire/ -- Funxional Therapeutics Ltd
(Funxional) has announced today the successful completion of the first Phase I
study with FX125L, an orally available small molecule which belongs to a new
therapeutic class named Broad Spectrum Chemokine Inhibitors (BSCIs).
The Phase I, single ascending dose study was conducted in the United States.
FX125L was well tolerated at all doses studied and no serious adverse events or
subject withdrawals were observed. The pharmacokinetics of FX125L was linear
over the wide dose range studied and consistent with once-daily oral dosing for
patients.
We are extremely pleased with the outcome of this initial clinical study with
FX125L, said Konstantinos Efthymiopoulos, CEO of Funxional Therapeutics. The
results in humans are consistent with the preclinical data, suggesting that
FX125L has a very wide safety margin, and confirmed the excellent drug-like
profile of FX125L.
About Funxional Therapeutics Ltd.
Funxional Therapeutics is a privately held, clinical stage pharmaceutical
company based in Cambridge (UK) which focuses on novel anti-inflammatory
therapies. FXT is managed by a very experienced team and is financed by Index
Ventures and Novo A/S, while its shareholders also include Ipsen and Cambridge
University. FXT has research and office facilities in Cambridge.
For more information about FXT, please visit our web site
(http://www.funxionaltherapeutics.com) or contact us by e-mail
(info@funxionaltherapeutics.com).
About BSCIs
BSCIs are anti-inflammatory compounds with an entirely novel mechanism of
action that involves the selective interaction with a well-characterized
receptor, resulting in a potent inhibition of inflammatory cell migration. The
compounds are anticipated to have broad applicability in inflammatory diseases.
BSCIs are one of the three proprietary technology platforms in FXT's portfolio
all of which originated in the University of Cambridge. BSCIs were discovered
based upon a strategy that exploits functional screening to develop novel new
classes of drugs. FX125L is the lead drug candidate in this novel class, while
other BSCIs have been identified as back up molecules or as candidates for
development as topical anti-inflammatory agents.
For enquiries regarding this press release, please contact Konstantinos
Efthymiopoulos, CEO of Funxional Therapeutics, at +44-1223-451095.
SOURCE: Funxional Therapeutics Limited
For enquiries regarding this press release, please contact Konstantinos
Efthymiopoulos, CEO of Funxional Therapeutics, at +44-1223-451095
Comments